
Indian firms accelerate overseas deals as domestic growth slows
Indian companies are stepping up outbound M&A as domestic growth slows, led by Sun Pharmaceuticals’ $11.75 billion acquisition of Organon—the largest Indian cross-border deal in years—alongside other big buys by Tata Motors, Coforge, and the Bajaj Group. In 2025, 162 Indian firms spent over $18 billion on outbound deals, a 34% rise, driven by a hunt for Western markets, brands, technology, and more resilient supply chains, supported by stronger balance sheets and easier global financing, though analysts warn large all-cash deals carry risk and domestic investment remains weak. The trend may accelerate with broader India-friendly trade deals and asset diversification by the next generation of Indian conglomerates.










